To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All

November 12, 2009

Princeton, NJ (RPRN) 11/12/09 — Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation.  According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation.  Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

Mesenchymal stem cells (MSCs), as distinct from the embryonic type, may be the key to healing diabetic foot ulcers.  These stem cells can differentiate into various cell types.  As a fetus develops, MSCs help drive its rapid initial growth; by the time we reach our teens, however, MSCs are mostly found in bone marrow.  

When wounded or burned, our skin craves MSCs, which it harbored when first growing.  In fact, recent studies show that surgically moving these cells from bone marrow onto hard-to-heal wounds accelerates healing.  

In contrast to surgically removing MSCs from bone marrow—a painful, time consuming and expensive process—a new topical drug, the novel angiotensin analog DSC127, appears to activate the mesenchymal stem cells in a patient’s body. 

“It appears that DSC127 directs MSCs to the injury site, mobilizing them to help repair wounded or burned skin, accelerate healing and reduce scar formation,” said Edward J. Quilty, Chairman & CEO of Derma Sciences Inc.  Based in Princeton, New Jersey, Derma Sciences develops, manufactures, and markets innovative wound care products.  “DSC127,” Quilty observed, “thus works as a catalyst for a stem cell treatment that is free of both the ethical controversies surrounding the medical use of fertilized embryos as well as potentially painful surgical interventions.”

Currently in a 75-patient Phase II diabetic foot ulcer clinical trial being conducted at some of the nation’s top institutions, the drug is being considered for additional indications including venous leg ulcers, arterial ulcers, pressure ulcers, thermal and chemical wounds, and scar prevention.  Pre-clinical animal studies have demonstrated the efficacy of the compound in accelerating healing and reducing scar formation. 

If DSC127 is approved for market, patients with diabetic foot ulcers may find a solution already exists within their own bodies.  For more information, visit www.dermasciences.com.

Media Contact Name: Janet Vasquez
Media Phone: 212-825-3210
Media Web Address: http://www.irgnews.com
Company Web Address: http://www.dermasciences.com
About the author:

Janet Vasquez, Director of Corporate Communications

About IRG

We are The Investor Relations Group (IRG), a full-service corporate communications firm that provides investor relations and public relations services to nano-, micro- and small-cap companies providing them with the equivalent in-house services of a large-cap company.

http://www.investorrelationsgroup.com

Click here to see all news from this author/company

Filed Under: Article-byline, BREAKING NEWS, FDA- Pharmaceutical news

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Portable Road Weather Information System (RWIS) Available

Nashville, TN 08/03/15 · Digital Traffic Systems, Inc. of Ashland, Virginia, announces...

Dry Paddleboarding Across Canada

Uxbridge, ON 08/03/15 · Uxbridge, August 3rd, 2015 - Standup Paddleboarding (SUP)...

Le Petit Kids, first childrens outlet sale 30-70%

Los Angeles, CA 08/01/15 · Americas very first kids designer outlet is announcing...

Neurobiologix Launches Methylation Complete Sublingual Enhanced Formula

Austin, TX 07/28/15 · Sublingual Formula Now Includes Additional Bioactive B12 For...

DEA ANNOUNCES 10th NATIONAL PRESCRIPTION DRUG TAKE-BACK

Washington, DC 07/28/15 · DEA Acting Administrator Chuck Rosenberg today announced that...

Publish your press release to 100 digital business news site for $59

New York, NY 07/20/15 · Your press release to be featured on at...

Recombinetics and Newborn Foundation Launch 
Newborn Health Research Institute

SAINT PAUL, MN 07/17/15 · Recombinetics and Newborn Foundation Launch 
Newborn Health Research...

InCycle Becomes Azure Gold Partner

SEATTLE, WA 07/13/15 · InCycle Software, today announced it has achieved a...

Ultraseal's new R-FL-Duplex+ machine sparks interest in casting impregnation

Dusseldorf, Germany 07/08/15 · Ultraseal International attracted great interest in its R-FL-Duplex+...

Dropout announces new website for 2015

London, UK 07/08/15 · The Dropout team are proud to announce the...